Clinical characteristics, post-treatment assessment and prognostic factors affecting patient survival of patients at 65 years of age or older with hodgkin lymphoma: A retrospective multicenter study from Turkey

Basit Öğe Kaydı
dc.authorscopusid55274431700
dc.authorscopusid8842895600
dc.authorscopusid36643942800
dc.authorscopusid55212747300
dc.authorscopusid56229840900
dc.authorscopusid53983007800
dc.authorscopusid57007882600
dc.contributor.authorBerber I.
dc.contributor.authorErkurt M.A.
dc.contributor.authorKeklik M.
dc.contributor.authorDogu M.H.
dc.contributor.authorTerzi H.
dc.contributor.authorPala C.
dc.contributor.authorSari H.I.
dc.date.accessioned2024-08-04T19:59:29Z
dc.date.available2024-08-04T19:59:29Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: During the last three decades, major advances have been made in the therapy of Hodgkin's lymphoma. However, despite these advances, Hodgkin's lymphoma has a poor prognosis in the elderly. The proportion of Hodgkin's lymphoma patients aged > 60 ranges in the different reports between 15% and 35%. This study aimed to examine clinical characteristics, treatment outcomes and prognostic factors affecting patient survival in Hodgkin's lymphoma patients aged 65 years or older. Material methods: Hodgkin's lymphoma patients at 65 years of age and older managed within last 5 years in a total of 5 centers in Turkey were retrospectively assessed. Results: The median age of a total of 32 patients was 71 (65-83) years. Elderly patients presented more frequently with B symptoms, elevated sedimentation rate, mixed cellularity histologic subtype and comorbid disease. Less frequent were bulky disease, bone marrow involvement, and the application of autologous stem cell transplantation. The nodular lymphocyte predominant subtype and lymphocyte rich subtype were not observed at all. Eastern Cooperative Oncology Group, ferritin, total protein, and histological type were significant predictors affecting survival (p<0.05). Conclusions: Hodgkin's lymphoma is a more fatal disease in 65 years of age or older, when compared to the young population. Tumor biology, older age itself, and other factors related to comorbidity probably contribute to the worse outcome of elderly patients. Further large-scale studies are needed to better investigate the factors that were significant predictors of patient survival.en_US
dc.identifier.endpage1202en_US
dc.identifier.issn0393-6384
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-84950279545en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1195en_US
dc.identifier.urihttps://hdl.handle.net/11616/90653
dc.identifier.volume31en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherA. CARBONE Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectElderly patientsen_US
dc.subjectHodgkin lymphomaen_US
dc.subjectPrognostic factorsen_US
dc.titleClinical characteristics, post-treatment assessment and prognostic factors affecting patient survival of patients at 65 years of age or older with hodgkin lymphoma: A retrospective multicenter study from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu